Ignite Creation Date:
2024-05-05 @ 4:40 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00291057
Status:
TERMINATED
Last Update Posted:
2013-12-23
First Post:
2006-02-10
Brief Title:
Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice
Sponsor:
Taro Pharmaceuticals USA
Organization:
Taro Pharmaceuticals USA
Study Overview
Official Title:
Phase II Multi-center Open-Label Safety and Tolerance Study of a Novel Malathion Formulation in Infants and Toddlers With Pediculosis Capitis
Status:
TERMINATED
Status Verified Date:
2013-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Lack of enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In a previous phase II study the safety and efficacy of a novel formulation of malathion 05 was evaluated in patients 2 years of age and older Based on the results of that study this formulation is currently in a phase III study for that population
The current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age
The current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None